THERAPEUTIC EFFICACY OF APOMORPHINE COMBINED WITH AN EXTRACEREBRAL INHIBITOR OF DOPAMINE RECEPTORS IN PARKINSON'S DISEASE

@article{Corsini1979THERAPEUTICEO,
  title={THERAPEUTIC EFFICACY OF APOMORPHINE COMBINED WITH AN EXTRACEREBRAL INHIBITOR OF DOPAMINE RECEPTORS IN PARKINSON'S DISEASE},
  author={Giovanni Umberto Corsini and Maria Del Zompo and Gian Luigi Gessa and Alfonso Mangoni},
  journal={The Lancet},
  year={1979},
  volume={313},
  pages={954-956}
}
Apomorphine in combination with a peripheral dopamine receptor blocker (domeperidone) was administered to four parkinsonian patients in a double-blind placebo-controlled study. The therapeutic efficacy of apomorphine was not reduced by domperidone, while nausea, drowsiness, sedation, and arterial hypotension were prevented. Combination of domperidone with dopamine agonists may result in more effective treatment of Parkinson's disease. 
Drugs acting on dopamine receptors: usefulness of a peripheral blocker in Parkinson's disease.
TLDR
The therapeutic efficacy of apomorphine was not antagonized by domperidone while nausea, drowsiness, sedation and arterial hypotension were prevented, which makes the clinical use of dopamine agonists in Parkinson's disease more feasible.
Bromocriptine and domperidone in the treatment of Parkinson disease
In a single-blind trial of therapy in 20 patients with idiopathic Parkinson disease, domperidone prevented nausea and vomiting induced by bromocriptine without diminishing beneficial central effects.
Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson’s disease
  • F. Grandas
  • Medicine
    Expert review of neurotherapeutics
  • 2013
TLDR
The therapeutic effect of continuous apomorphine infusion is reviewed, practical recommendations on its use are provided and the patient's quality of life is improved.
Subcutaneous apomorphine in Parkinson's disease
TLDR
Motor function in patients who are disabled by parkinsonian on-off oscillations can be significantly improved by administration of subcutaneous apomorphine by diurnal infusion or intermittent injection and has produced prolonged benefit in patients suffering from the most intractable complication of prolonged L-dopa therapy.
Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients
TLDR
This study in drug-free parkinsonian patients demonstrated that terguride is able to improve the neurological symptoms similar to DA agonists, but without their typical side effects.
Domperidone and Parkinson's disease.
  • J. Parkes
  • Medicine
    Clinical neuropharmacology
  • 1986
TLDR
It has not as yet proved possible to separate the nigrostriatal from other central effects of dopamine, although peripheral effects of levodopa have been limited in two different ways.
Use of apomorphine in Parkinson's disease.
Apomorphine is a dopamine agonist administered subcutaneously as intermittent injections or in a continuous infusion. It is useful in managing advanced Parkinson's disease, and provides an
Apomorphine in the treatment of Parkinson's disease
TLDR
The historical background, structure, mechanism of action, pharmacologic properties, clinical trials, indications and side effects, as well as avenues of further research, of apomorphine are reviewed.
Cardiovascular reflexes in Parkinson's disease: Effect of domperidone and apomorphine
TLDR
Apomorphine altered cardiovascular reflexes to a greater degree in patients who received the drug for the first time than in chronically treated patients, and the changes were antagonized by domperidone, a peripheral dopamine receptor antagonist.
The clinical use of apomorphine in Parkinson's disease
TLDR
Certain indications for its use are formulated, together with suggested approaches to modify patients' oral drug regimes so that apomorphine can best be deployed to improve their quality of life.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 11 REFERENCES
Treatment of parkinsonism with bromocriptine.
TLDR
Bromocriptine has been administered to parkinsonian patients and was found to have a potent therapeutic action, quite comparable to that of levodopa.
Schizophrenic symptoms improve with apomorphine.
Eighteen chronic schizophrenic patients received subcutaneous doses of apomorphine, a dopamine receptor agonist, and of placebo in separate trials. A significant improvement in psychotic symptoms
Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor.
TLDR
Four patients affected by Huntington's chorea with a well defined family history of the disease were injected intramuscularly with apomorphine hydrochloride in nonemetic doses, and all patients showed a marked decrease in abnormal involuntary movements.
Injected apomorphine and orally administered levodopa in Parkinsonism.
TLDR
The dichotomy between synergistic and antagonistic effects may be explained by the molecule of apomorphine, part of which resembles dopamine and the other resembles phenylethylamine, which can displace neurotransmitters from cellular sites.
Apomorphine in Huntington's chorea: clinical observations and theoretical considerations.
TLDR
Optimal doses ranged from 1–2 mg across patients, producing a significant reduction in AIM for the entire hour of observations, and theoretical interpretations of these effects regarding dopaminergic receptor stimulation and/or blockade by apomorphine are discussed.
Domperidone, a novel and safe gastrokinetic anti-nauseant for the treatment of dyspepsia and vomiting.
TLDR
A new potent anti-nauseant, which in contrast to available anti-emetics does not provoke extrapyramidal or adrenolytic adverse effects, also enhances gastric emptying motility and appears to be a safe and effective treatment for patients with dyspepsia or vomiting.
HYPOTENSION PRODUCED BY INTRAVENOUS APOMORPHINE IN THE ANAESTHETIZED DOG IS NOT CENTRALLY MEDIATED
TLDR
It is concluded that the hypotension seen with intravenous apomorphine cannot be explained by a central site of action and the animals showed a marked hypotension on intra‐vertebral or intracisternal injection of clonidine.
Similarities between neurologic effects of L-dopa and of apomorphine.
L-DOPA is a precursor for the biosynthesis of both melanins and catecholamines. Both groups of substances are diminished within the Parkinsonian brain.1 2 3 L-dopa administration might therefore in...
Inhibition of dopamine receptors in the stomach: an explanation of the gastrokinetic properties of domperidone.
TLDR
The results strongly suggest that dopamine or/and secretin are involved in the local feedback control of gastric motility; the action of secretin may be direct or indirect by release of dopamine.
Pharmacology and neurochemistry of apomorphine.
TLDR
This chapter discusses the pharmacology and neurochemistry of apomorphine, which was first employed as a powerful emetic agent and is metabolized by O-glucuronidation, O-methylation, and, probably, by N-demethylation.
...
1
2
...